What is the regulatory status of Melanotan I?

Melanotan I regulatory status: Approved (Scenesse implant for EPP) in the United States; WADA status not on prohibited list; research level phase iii in epp; off-label tanning use. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For anabolic and recovery use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What is the mechanism of action of Melanotan I?

Selective melanocortin-1 receptor (MC1R) agonist. Increases eumelanin production in melanocytes. Provides photoprotection. Lacks the MC4R-mediated central effects (libido, appetite, sexual response) of Melanotan II. For anabolic and recovery applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Selective melanocortin-1 receptor (MC1R) agonist. The body composition / training interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What does Melanotan I stack well with?

For body composition / training protocols, Melanotan I pairs with compounds on complementary pathways: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500. These pairings are selected because they engage independent receptor systems from Melanotan I's primary mechanism (Selective melanocortin-1 receptor (MC1R) agonist), producing additive or synergistic effects rather than receptor competition.

What should I look for in Melanotan I sourcing and quality?

Acceptable Melanotan I certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 1646 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

How long until I see results from Melanotan I?

Acute effects from Melanotan I appear within hours of dosing for receptor-level changes. anabolic and recovery endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

What is the evidence base for Melanotan I?

Melanotan I's evidence base sits at phase iii in epp; off-label tanning use. The references on this page summarise 1 primary publication supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The body composition / training interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

Home/ Compounds/ Melanotan I

Melanotan I

Body Composition

For the body-composition and physique community, Melanotan I is run inside a training-driven framework where the compound supports rather than substitutes for stimulus and nutrition. Selective melanocortin-1 receptor (MC1R) agonist Increases eumelanin production in melanocytes. Provides photoprotection. Lacks the MC4R-mediated central effects (libido, appetite, sexual response) of Melanotan II.. The ~2-30 days (implant); ~30 min SubQ pharmacokinetic profile determines training-day versus rest-day dosing, while the subq/implant (approved formulation) administration shapes injection-site rotation and protocol planning.

Body Composition / Training Applications

StrengthInjury RecoveryRecoveryBody RecompositionLean Mass

Key Takeaways

Body composition lens: response to Melanotan I is proportional to training stimulus and nutritional adequacy.
Mechanism: Selective melanocortin-1 receptor (MC1R) agonist.
Body composition dose: 0.5-1 mg 1x daily during loading; less frequent maintenance via subq/implant (approved formulation); effects visible at week 4-8 with adequate training and protein.
Cycle structure: 8-12 weeks on, 4 weeks off; training-day or daily dosing depending on half-life.
Performance stack partners: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500.

Body Composition / Training Mechanism

Selective melanocortin-1 receptor (MC1R) agonist. Increases eumelanin production in melanocytes. Provides photoprotection. Lacks the MC4R-mediated central effects (libido, appetite, sexual response) of Melanotan II. The body composition layer follows: how the compound contributes to anabolic substrate, how it shapes the recovery window between training sessions, how training-day dosing differs from rest-day dosing, and which structural-adaptation dimension (hyperplasia or hypertrophy) is most affected by Melanotan I.

Recovery window and training frequency

The most reliably reported effect of Melanotan I in athlete populations is on the recovery window between sessions. Faster connective tissue recovery, better sleep quality, and reduced systemic inflammation translate into more high-quality training days per cycle. This is the practical mechanism by which body composition shifts for most users — not via dramatic acute anabolic effect but via more accumulated quality training.

Training-day versus rest-day dosing

Many peptides in this category respond better to training-day-only versus rest-day-included dosing. Melanotan I with a ~2-30 days (implant); ~30 min SubQ half-life of ~2-30 days (implant); ~30 min SubQ is long-lived enough that daily dosing matters less than total exposure per cycle. The practical dosing schedule reflects this.

Hyperplasia and structural adaptation

Where Melanotan I demonstrates effects on fibre count rather than fibre size — hyperplasia rather than hypertrophy — the structural adaptation matters more than the acute anabolic signal. Most peptides in this category contribute to the hypertrophic rather than hyperplastic adaptation, with the magnitude depending on training stimulus.

Body Composition / Training Applications

Strength

For strength, Melanotan I integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Body Recomposition

The body composition community converges on Melanotan I for body recomposition with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Anabolic Support

Anabolic Support responds to Melanotan I with effect sizes proportional to training stimulus and nutritional adequacy. Users running aggressive caloric deficits see reduced response; users in surplus with adequate protein see proportionally larger response. Programming the inputs is half the protocol.

Injury Recovery

For injury recovery, Melanotan I integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	0.5-1 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1.5-1 mg	4–6 weeks initial cycle
Body Composition focus	SubQ	0.5-1 mg	1x daily during loading; less frequent maintenance
Maintenance phase	SubQ	1.5-1 mg	Ongoing with periodic pauses

Dose timing for Melanotan I is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Melanotan I stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from performance coaches and athletes.

Melanotan I + IGF-1 LR3: Binds the IGF-1 receptor with full agonist activity. Pairs naturally with Melanotan I's mechanism in body composition / training protocols.
Melanotan I + CJC-1295 + Ipamorelin Blend: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. Pairs naturally with Melanotan I's mechanism in body composition / training protocols.
Melanotan I + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Melanotan I's mechanism in body composition / training protocols.
Melanotan I + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Melanotan I's mechanism in body composition / training protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Approved (Scenesse implant for EPP) Research: Phase III in EPP; off-label tanning use

Hyperpigmentation (intended). Nausea on initial doses. Watch for new/changing moles. Avoid in personal/family melanoma history.

Lens-specific safety considerations for body composition / training use of Melanotan I: Hyperpigmentation (intended). Nausea on initial doses. Watch for new/changing moles. Avoid in personal/family melanoma history. Additional body composition / training monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Afamelanotide in erythropoietic protoporphyria

PMID 26177253

Melanotan I vs Related Peptides

Compound	Profile	Onset	Best For
Melanotan I	α-MSH analogue (long-acting)	~2-30 days (implant); ~30 min SubQ	Body Composition
IGF-1 LR3	Modified insulin-like growth factor 1	~20-30 hr (vs ~10 min for native IGF-1)	A modified IGF-1 with a 13-amino-acid N-terminal extension and Arg substitution that resists IGFBP binding — extending half-life from 10 minutes to roughly a day
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

How does Melanotan I compare to AAS for body composition?

Peptide therapeutics including Melanotan I produce more modest body composition shifts than anabolic-androgenic steroids and operate on different mechanisms with substantially different side-effect profiles. The compound is most-appropriate for users prioritising long-term sustainability and clean blood work over maximum acute mass.

Training-day only or daily dosing?

For most peptide compounds with short-to-moderate half-life, training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The choice depends on the user's training volume and the compound's pharmacokinetics. Daily dosing for 4-7 days is the default; training-day-only protocols are appropriate for lower-volume programmes.

Best stack pairing for lean mass?

The canonical lean mass stack pairs Melanotan I with a complementary GH-axis component, a connective-tissue support peptide, and — in advanced protocols — an anabolic-supportive component. Specific pairings depend on which dimension of body composition is prioritised: pure mass, mass-and-fat-loss, or recovery-focused.

Should I cycle Melanotan I?

Standard cycle structure for body composition use is 8–12 weeks on, 4 weeks off. Continuous indefinite use is not advised for most compounds in this class; the off-period preserves dose response and reduces cumulative downregulation. Cycle stacking with complementary peptides is common in advanced protocols.

How does Melanotan I's half-life affect dosing?

Melanotan I has a plasma half-life of ~2-30 days (implant); ~30 min SubQ, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 1x daily during loading; less frequent maintenance dosing at 0.5-1 mg per dose explains the typical onset timeline for anabolic and recovery endpoints.

Will Melanotan I actually increase lean mass?

Melanotan I's effect on body composition depends on which dimension of the anabolic cascade it engages. Direct anabolic pathway engagement is not the principal mechanism, but contributions to recovery, connective tissue, and inflammatory tone produce measurable body-composition shifts in trained users. Effect size is proportional to training stimulus and nutritional adequacy.

Clinical Protocol

Start a Melanotan I Protocol

Alukard provides physician-supervised body composition protocols with GMP-certified Melanotan I and GMP-certified compounds and training-aware dosing guidance.

Get Protocol

Quick Facts

Molecular weight: 1646 Da
Sequence length: 13 aa
Half-life: ~2-30 days (implant); ~30 min SubQ
WADA: Not on prohibited list
FDA: Approved (Scenesse implant for EPP)
Research: Phase III in EPP; off-label tanning use

Stack Partners

IGF-1 LR3

CJC-1295 + Ipamorelin Blend

TB-500

BPC-157

Tesamorelin + Ipamorelin Blend

Research Note

All body composition / training applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Melanotan I unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised body composition protocols

Start Your Body Composition / Training Protocol for Melanotan I

Alukard provides physician-supervised body composition protocols with GMP-certified compounds and training-aware dosing guidance.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised